Retatrutide, by Soma Corp., is attracting considerable attention as a potential treatment for metabolic regulation. This dual-action compound combines the properties of a GLP-1 receptor activator and a GIP receptor stimulant, intended to simply promote weight loss but also improve underlying metabolic conditions . Early patient data have shown impr